COVID Testing Kits
Epigentek Inc CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit (48 Assays)
For high throughput screening of compounds that inhibit the proprotein convertase cleavage of SARS-CoV-2
Sino Biological SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein, Endotoxin-Free 1mg
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) (YP_009724390.1) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus.
Meso Scale Discovery SPLEX SARSCoV2 Spike
The S-PLEX SARS-CoV-2 Spike Kit from Meso Scale Diagnostics is an electrochemiluminescent immunoassay that quantitatively measures antibodies specific to the SARS-CoV-2 spike protein This multiplex assay simultaneously measures IgG IgM and IgA antibodies and provides a semiquantitative result to aid in assessing recent or prior SARS-CoV-2 infection The kit includes a 96-well plate coated with recombinant SARS-CoV-2 spike protein as well as detection antibodies calibrators controls diluent and other necessary reagents Results are obtained in just a few hours using Meso Scale Diagnostics instrumentation and software
Meso Scale Discovery R-PLEX SARS-CoV-2 Spike ASYQP
The R-PLEX SARS-CoV-2 Spike Assay is a multiplex immunoassay panel that detects antibodies to the SARS-CoV-2 spike protein in human serum and plasma It uses Meso Scale Discovery electrochemiluminescence technology and provides quantitative results for IgG IgM and IgA antibodies The assay has high sensitivity and specificity and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2 indicating recent or prior infection It requires a small sample volume and provides results in under 3 hours The kit includes a 96-well plate calibrators controls diluent and substrate
Meso Scale Discovery S-PLEX SARS-CoV-2 N Kit
The S-PLEX SARS-CoV-2 N Kit is a multiplex immunoassay panel for the simultaneous qualitative detection of nucleocapsid protein antigens to SARS-CoV-2 in serum plasma and saliva This assay utilizes electrochemiluminescence (ECL) on the SECTOR Imager 2400 platform The kit includes a plate coated with capture antibodies detection antibodies conjugated to ruthenium and calibrators and controls needed to run the assay Results are obtained within 3 hours This is an in vitro diagnostic test for aid in identifying individuals with an adaptive immune response to SARS-CoV-2 indicating recent or prior infection
Bioss SARS-CoV-2 S-Protein ACE2 Bind
SARS-CoV-2 S-Protein ACE2 Binding Domain Primary Antibody Unconjugated Host Species Mouse Target Species SARS-CoV-2 Clonality Monoclonal Applications WB 2G1Concentration Lot Dependent Size 100 ul Storage Buffer PBS 50% glycerol and 5 mm NaN3
Genscript Corporation cPass SARS-CoV-2 Neutralizati
The b GenScript SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit /b can detect circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain of the viral spike glycoprotein (RBD) with the ACE2 cell surface receptor The assay detects any antibodies in serum and plasma that neutralize the RBD-ACE2 interaction The test is both species and isotype independent br/ br/ The b SARS-CoV-2 sVNT Kit /b is a blocking ELISA detection tool which mimics the virus neutralization process The kit contains two key components the Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD fragment (HRP-RBD) and the human ACE2 receptor protein (hACE2) The protein-protein interaction between HRP-RBD and hACE2 can be blocked by neutralizing antibodies against SARS-CoV-2 RBD br/ First the samples and controls are pre-incubated with the HRP-RBD to allow the binding of the circulating neutralization antibodies to HRP-R
Genscript Corporation SARS-CoV-2 Spike 484Q Antibo
SARS-CoV-2 Spike (484Q) Antibody (Q8) mAb Mouse is specific for 484Q site of B 1 617 SARS-CoV-2 This product can recognize single mutant (E484Q) and double mutant (L452R E484Q) but can not recognize the wild type and single mutant (L452R)
Genscript Corporation SARS-CoV-2 Spike protein S1 O
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases Recently the new B 1 1 529 variant was confirmed in South Africa and preliminary evidence suggests an increased risk of reinfection with this variant The B 1 1 529 variant was first reported to WHO on 24 November 2021 and WHO has designated this variant as a VOC (Variant of Concern) named Omicron There are more than 30 mutations in the spike protein